Evidence map›Paper›PMID 32021975›Full record

ArticleEuropean journal of obstetrics & gynecology and reproductive biology: X2020

MicroRNA-135a promotes proliferation, migration, invasion and induces chemoresistance of endometrial cancer cells.

Jiping Wang, Li Zhang, Wenyan Jiang, Rongkui Zhang, Bei Zhang, Aidaeraili Silayiding, Xiumei Duan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of obstetrics & gynecology and reproductive biology: X, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?International journal of molecular sciences · 2022
    Review
  16. MicroRNA-641 Inhibits Endometrial Cancer Progression via Targeting AP1G1.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  17. Reference Genes for qPCR-Based miRNA Expression Profiling in 14 Human Tissues.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiping WangDepartment of Radiology, the First Hospital, Jilin University, 130021, China.
Li ZhangDepartment of Radiology, the First Hospital, Jilin University, 130021, China.
Wenyan JiangDepartment of Radiology, the First Hospital, Jilin University, 130021, China.
Rongkui ZhangDepartment of Radiology, the First Hospital, Jilin University, 130021, China.
Bei ZhangDepartment of Radiology, the First Hospital, Jilin University, 130021, China.
Aidaeraili SilayidingDepartment of Pathology, the First Hospital, Jilin University, 130021, China.
Xiumei DuanDepartment of Pathology, the First Hospital, Jilin University, 130021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsMicroRNAs play essential roles in tumorigenesis and progression in various cancers including endometrial cancer. Here we assessed the role of miR-135a on proliferation, chemosensitivity, migration and invasion of endometrial cancer cells.

methodsWST-1 assay was performed to examine the proliferation of HEC-1-B and ISHIKAWA endometrial cancer cells with altered expression of miR-135a, with or without cisplatin treatment. Transwell migration and matrigel invasion assays were used to assess the migration and invasion of endometrial cancer cells. The Caspase-Glo3/7 assay was used to examine the effect of miR-135a on cisplatin-induced apoptosis of endometrial cancer cells. The dual-luciferase reporter assay was conducted to validate the putative binding site.

resultsUpregulation of miR-135a improved the proliferation, and promoted migration and invasion of endometrial cancer cells. Furthermore, miR-135a decreased the sensitivity of HEC-1-B and ISHIKAWA cells after cisplatin treatment. The cisplatin-induced apoptosis in endometrial cancer cells was inhibited by miR-135a by regulation of BAX and Bcl-2 expression. Meanwhile, miR-135a could regulate epithelial to mesenchymal transition (EMT) by altering the expression of E-cadherin, N-cadherin, snail and Vimentin in endometrial cancer cells. Further study showed that the expression levels of PTEN and p-AKT in endometrial cancer cells were changed after aberrant expression of miR-135a.

conclusionMiR-135a played important roles in tumorigenesis and disease progression of endometrial cancer by regulating proliferation and chemosensitivy of endometrial cancer cells by targeting AKT signaling pathway. Our study indicates that miR-135a might act as a potential biomarker to predict chemotherapy response and prognosis in endometrial cancer.

Indexed as

AKTApoptosisEndometrial cancermiR-135a

Identifiers

PMID32021975
PMCPMC6994408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.